A Study of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 Tumor Marker Expressions in Neoplastic and Non -neoplastic Gall Bladder Lesions and their Clinico-pathological Correlation

Background: Worldwide gall bladder cancer (GBC) is known to be the commonest malignant tumour of the biliary tract. It is the most aggressive carcinoma of the biliary tract with short median survival from the time of diagnosis. The aggressive biologic behaviour of the carcinoma and non-availability of sensitive screening tests for early detection may be responsible for the poor prognosis associated with GBC. Material and Methods: Patients diagnosed with neoplastic and non-neoplastic gallbladder lesions in the Department of Pathology, Subharti Medical College in India were included in the study. Gall bladder biopsies findings and the clinic-pathological data were compiled and different immune-markers  diagnostic and therapeutic usefulness were studied . Results: 24 (24.0%) of the cases were in the age group of 51-60 Years.  In 38 (38.0%) of the cases the site of lesion was Fundus. 55 (55.0%) of cases had associated stones. 36 (36.0%) of them had P53: strong over expression, 40 (40.0%) of the them had ki67: strong over expression, 25 (25.0%) had EGFR: strong over expression whereas negative expression for  Her2/Neu was found in 61 (61.0%) of the cases. Cyclin D1: moderate over expression was found in 27 (27.0%) of them and moderate over expression of E-cadherin were found in  22 (23.2%) cases. Conclusions: Novel prognostic biomarkers could bring about the needed breakthrough in gall bladder cancer diagnosis and treatment. We conclude that the biomarkers studied by us  may help in the identification of cases who may benefit tremendously from adjuvant and targeted therapies. Key words: Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67,  p53, tumour marker, neoplastic , non –neoplastic, Gall bladder lesions.